In a multinational study of 6500 male patients with BRCA1 and BRCA2 pathogenic sequence variants (PSV), two regions in BRCA2 (c.756-c 1000 and c.7914þ) were identified as high risk for developing Gleason 8b prostate cancer—this was more prominent in PSVs in PCCRs [103]. This evidence concerns the gene BRCA1 and prostate cancer.